Moderna, Inc. (NASDAQ:MRNA) Insider Sells $334,000.00 in Stock

Moderna, Inc. (NASDAQ:MRNAGet Rating) insider Juan Andres sold 2,000 shares of the stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $167.00, for a total value of $334,000.00. Following the completion of the transaction, the insider now owns 10,367 shares of the company’s stock, valued at approximately $1,731,289. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Juan Andres also recently made the following trade(s):

  • On Wednesday, July 13th, Juan Andres sold 2,000 shares of Moderna stock. The stock was sold at an average price of $168.88, for a total value of $337,760.00.
  • On Wednesday, July 6th, Juan Andres sold 2,000 shares of Moderna stock. The stock was sold at an average price of $154.85, for a total value of $309,700.00.
  • On Friday, July 1st, Juan Andres sold 6,000 shares of Moderna stock. The stock was sold at an average price of $150.00, for a total value of $900,000.00.
  • On Tuesday, May 31st, Juan Andres sold 749 shares of Moderna stock. The stock was sold at an average price of $145.40, for a total value of $108,904.60.
  • On Tuesday, May 10th, Juan Andres sold 195 shares of Moderna stock. The stock was sold at an average price of $133.71, for a total value of $26,073.45.
  • On Wednesday, May 4th, Juan Andres sold 2,000 shares of Moderna stock. The stock was sold at an average price of $153.23, for a total value of $306,460.00.
  • On Friday, April 29th, Juan Andres sold 2,000 shares of Moderna stock. The stock was sold at an average price of $150.00, for a total value of $300,000.00.

Moderna Trading Down 3.2 %

Shares of NASDAQ:MRNA opened at $163.52 on Friday. The stock has a market capitalization of $65.04 billion, a price-to-earnings ratio of 4.81, a PEG ratio of 0.95 and a beta of 1.65. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.56 and a current ratio of 1.77. The stock’s 50-day simple moving average is $146.00 and its two-hundred day simple moving average is $155.44. Moderna, Inc. has a 52-week low of $115.61 and a 52-week high of $497.49.

Moderna (NASDAQ:MRNAGet Rating) last announced its earnings results on Wednesday, May 4th. The company reported $8.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.18 by $3.40. The business had revenue of $6.07 billion for the quarter, compared to analysts’ expectations of $4.43 billion. Moderna had a return on equity of 121.86% and a net margin of 64.77%. The business’s revenue for the quarter was up 213.2% on a year-over-year basis. During the same period last year, the firm posted $2.84 earnings per share. Analysts expect that Moderna, Inc. will post 27.26 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Field & Main Bank purchased a new position in Moderna in the fourth quarter worth about $25,000. Confluence Wealth Services Inc. bought a new position in shares of Moderna in the fourth quarter worth about $25,000. Standard Family Office LLC bought a new position in shares of Moderna in the fourth quarter worth about $25,000. Reilly Financial Advisors LLC bought a new position in shares of Moderna in the fourth quarter worth about $26,000. Finally, Fieldpoint Private Securities LLC raised its stake in shares of Moderna by 425.0% in the fourth quarter. Fieldpoint Private Securities LLC now owns 105 shares of the company’s stock worth $27,000 after buying an additional 85 shares during the period. 61.20% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on MRNA shares. Piper Sandler cut their target price on Moderna from $348.00 to $214.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 17th. Morgan Stanley increased their price objective on Moderna from $205.00 to $217.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 12th. Finally, SVB Leerink dropped their price objective on Moderna from $80.00 to $70.00 and set an “underperform” rating on the stock in a research report on Tuesday, June 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Moderna currently has an average rating of “Hold” and a consensus target price of $228.00.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Read More

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.